Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P02794 (ferritin)
 17,525 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In 5 haemodialyzed patients with end-stage renal failure an effect of human recombinant erythropoietin (r-huEpo) on haemoglobin, haematocrit and iron metabolism was studied. After 12 weeks of the treatment, a significant increase in haemoglobin and haematocrit but significant decrease in plasma ferritin were noted. During r-huEpo treatment, one patients presented clinical symptoms of increased blood coagulation whereas another patients an increase in blood pressure. r-huEpo did not influence leukocytes and platelets count as well as liver function tests. Our results suggest, that r-huEpo is highly effective and safe in the treatment of anaemia in patients with chronic uraemia. Iron metabolism, blood pressure and blood coagulation must be monitored during therapy with r-huEpo.
 ...
PMID:[Treatment of anemia in patients with renal failure using erythropoietin obtained by genetic recombination]. 209 46

This study clarifies the correlation between guanidino compounds and other laboratory findings including peroxidative markers in the sera of patients undergoing regular haemodialysis. The concentration of guanidine, for example, correlates significantly with iron, ferritin, and malondialdehyde. Guanidine is synthesized from various guanidino compounds such as arginine, guanidinoacetic acid, creatinine, creatine, methylguanidine, guanidinosuccinic acid, and canavanine in vitro by the hydroxyl radical. These results suggest that guanidine is synthesized as a result of active oxygen, and demonstrates the importance of guanidine as an indicator of the peroxidative state in patients with uraemia.
 ...
PMID:Evidence for the role of active oxygen in guanidine synthesis in haemodialysis patients and in vitro. 314 21

The relations between plasma transferrin, iron status and plasma albumin were studied in 76 patients with chronic uremia (23 non-dialyzed, 18 peritoneal dialyzed and 35 hemodialyzed). Patients with reduced (grade O) hemosiderin marrow iron had higher plasma transferrin (P less than 0.001), lower serum iron (P less than 0.01), transferrin saturation (P less tha 0.001) and serum ferritin (P less than 0.001), and higher iron absorption (P less than 0.001) than patients with "normal" (grade 1+) marrow iron. There were no significant differences between transferrin levels in the three groups of uremic subjects, when patients with identical marrow iron grade were compared. Plasma transferrin was correlated both to serum ferritin (r = -0.59, P less than 0.001) and iron absorption (r = 0.56, P less than 0.001). Patients with grade O marrow iron had normal transferrin levels compared with a healthy control group of 75 subjects, while levels in patients with grade 1+ marrow iron were lower than in controls (P less than 0.001). Plasma albumin displayed significant variations between the groups, being almost normal in non-dialyzed, slightly lower in hemodialyzed and lowest in peritoneal dialyzed patients. There was no correlation between plasma transferrin and plasma albumin. Due to its close association with iron metabolism, plasma transferrin is unsuitable as a marker of protein depletion, whereas plasma albumin seems to be a better indicator of protein status in uremic subjects.
 ...
PMID:Plasma transferrin and the relation to iron status in patients with chronic uremia. 617 27

Serum erythropoietin (EPO) was measured in 64 children with chronic renal failure (CRF) by means of the fetal mouse liver cell assay. The results were compared with two control groups consisting of 20 healthy children and 10 with nonrenal anemia. EPO was analyzed according to the mode of treatment and the degree of uremia, anemia, hypoxemia, hyperparathyroidism, and body iron load. Mean EPO was 36 U/liter on conservative treatment (CT) (N = 30), similar to that in healthy children (35 U/liter) and in 15 children with renal transplants (TP, 39 U/liter), but significantly higher than that in 19 patients on regular dialysis (RDT; 16 U/liter) and lower than that in children with nonrenal anemia but with similar hemoglobin (230 U/liter). On CT, EPO was higher with severe uremia (SCr greater than 4 mg/dl) compared with moderate CRF and was inversely correlated with hemoglobin, but on a lower level compared with control, whereas on RDT the correlation became positive. By serial measurements, the decrease of EPO from CT to RDT was confirmed. An inverse relationship between EPO and p50 or the oxygen transport index was detected only on CT and after TP. EPO was inversely correlated with serum ferritin levels on HD. Between EPO and PTH, no correlation was found. Data demonstrate a negative feedback between EPO and the degree of hypoxia in children with CRF. On CT, this regulatory mechanism of erythropoiesis is acting on a lower level than it does in control subjects and is lost on RDT.
 ...
PMID:Serum erythropoietin levels in children with chronic renal failure. 658 79

The diagnostic usefulness of bone marrow hemosiderin, serum ferritin, transferrin saturation, mean corpuscular volume (MCV) and red cell protoporphyrin (EPP) in the evaluation of iron status in patients on chronic hemodialysis was studied in 39 subjects. The correlation between serum ferritin and the number of transfusions received per month was slightly higher (r = 0.717; p less than 0.001) than the correlation between bone marrow hemosiderin and transfusions (r = 0.685; p less than 0.01). Serum ferritin was useful in identifying subjects with both increased or reduced iron stores. In contrast, transferrin saturation could only be used for indicating iron overload. MCV for indicating iron deficiency, and EPP was not useful in either case. The abnormal increase of EPP in chronic uremia has not been previously described. It is unrelated to iron deficiency and is most probably explained by the known reduction in red cell ferrochelatase activity associated with chronic uremia. Serum ferritin is clearly the most useful diagnostic aid for assessing iron stores in patients on chronic hemodialysis. Whether ferritin is also the best predictor of response to iron therapy, cannot be determined on the basis of the present data.
 ...
PMID:Evaluation of iron status in patients on chronic hemodialysis: relative usefulness of bone marrow hemosiderin, serum ferritin, transferrin saturation, mean corpuscular volume and red cell protoporphyrin. 663 60

Iron absorption was measured by whole body counting, using 10 microCI 59Fe3+ and 10 mg Fe2+ as carrier, in 53 patients with chronic uremia (16 non-dialyzed, 18 peritoneal dialyzed, 19 hemodialyzed) and in 14 renal transplanted patients having normal kidney function. Bone marrow hemosiderin iron was assessed semiquantitatively after staining with Prussian blue, Iron absorption was clearly dependent on iron stores, being higher in patients with reduced marrow iron than in patients with adequate marrow iron stores (P less than 0.01) Hemodialysis patients had greater blood losses and significantly higher absorption than both non-dialysis and peritoneal dialysis patients. There were significant correlation between iron absorption and plasma transferrin (r = 0.56, P less then 0.001); and between log iron absorption and log serum ferritin (r = 0.80, P less than 0.01) in peritoneal dialysis patients. The results indicate that the regulatory mechanism which relates iron absorption to body iron stores is intact in patients with chronic uremia.
 ...
PMID:Iron absorption measured by whole body counting and the relation to marrow iron stores in chronic uremia. 680 44

The purpose of this study was to examine the accuracy of iron absorption calculated from the incorporation of radioiron into red cells (RCI), compared to measurement by the whole body counting technique (WBR). RCI of orally administered 59Fe, and absorption of 59Fe assessed by WBR were measured simultaneously in 53 chronic uraemic patients (16 nondialysed, 18 peritoneal dialysed, 19 haemodialysed), 14 renal transplanted patients with normal renal function, and 27 healthy subjects. In the majority of subjects RCI values were lower than corresponding WBR values, with mean red cell 59Fe utilization values (RCI/WBR ratio X 100) in the various groups from 78% to 93%. All groups demonstrated significant correlations between RCI and WBR with r values from 0.963 to 0.996 (P less than 0.001). RCI was higher in patients with reduced marrow iron stores than in patients with adequate iron stores (P less than 0.001), and was correlated both to plasma transferrin (r = 0.59, P less than 0.001) and serum ferritin (r = -0.88, P less than 0.001). In all groups there was good accuracy of calculated iron absorption (from RCI) compared to 'true' iron absorption (by WBR) with r values from 0.963 to 0.995 (P less than 0.001). Iron absorption measurement based on red cell incorporation appears to be a practical and accurate alternative to whole body counting, both in healthy subjects and in patients with chronic uraemia.
 ...
PMID:Iron absorption in patients with chronic uraemia. A comparative study using whole body counting and red cell incorporation of radioiron. 681 12

Radio-iron kinetic tests were performed in 7 patients with end-stage renal disease treated by hemodialysis; the study could be completed in 6 patients. The incorporation of radio-iron into the erythrocytes was 21% on average in patients with acute anemia. The red cell life-span determined in 4 patients became significantly shorter in 3 patients. Iron turnover in the bone marrow was significantly lower than normal, the rate of ineffective erythropoiesis being higher. Serum ferritin levels were significantly higher, and tissue and extravascular iron turnover was found to be enhanced compared to normal. At the same time, serum iron level was normal. The data on iron turnover indicated deficient hemopoiesis in the bone marrow, due partly to the lack of erythropoietin and partly to the insufficiency of the BFU-E (burst forming units) and CFU-E (colony-forming units) reserves. Undoubtedly, this was a consequence of the uremia.
 ...
PMID:Iron turnover in patients with chronic uraemia treated with hemodialysis. 718 45

Bone marrow haemosiderin iron was correlated with various laboratory parameters of iron status in order to define a reliable laboratory index of marrow iron stores. Marrow iron, serum iron, plasma transferrin, transferrin saturation, iron absorption, red cell iron incorporation and serum ferritin were measured in 21 non-dialysed, 20 peritoneal dialysed and 34 haemodialysed patients with chronic uraemia. Diagnostic accuracy of the laboratory tests in terms of diagnosing reduced marrow iron stores was expressed as the predictive value of a positive test and a negative test, and efficiency. Diagnostic efficiency of serum iron, plasma transferrin and transferrin saturation was too low to be of value in the individual patient. Iron absorption and red cell incorporation had a higher diagnostic efficiency, but are unpractical for routine use. Serum ferritin displayed a high diagnostic efficiency and appears to be a reliable index of marrow iron stores, suitable for sequential monitoring of iron status in uraemic subjects.
 ...
PMID:Diagnostic efficiency of various laboratory tests in the assessment of bone marrow iron stores in patients with chronic uraemia. 733 42

The present study aimed to assess the influence of long-term therapy with recombinant human erythropoietin (rHuEPO) for 12 months on follitropin (FSH), lutropin (LH), testosterone (TE) and estradiol (E2) serum concentrations in hemodialyzed males with chronic renal failure. Two groups of hemodialyzed males with chronic renal failure were examined. The first one consisted of 20 male patients with uraemia and renal anaemia (haematocrit value < 28%). Eleven of them were treated with rHuEPO for 12 months in order to achieve and maintain a target haematocrit value (Hct) of 30-35% (EPO group). The remaining 9 male patients were only carefully monitored both clinically and biochemically (No-EPO group). Patients of both groups (EPO and No-EPO) were intensively supervised according to the same clinical and biochemical protocol. Before (0) and after 3, 6, 9 and 12 months of the study, blood samples were withdrawn for the estimation of blood haemoglobin concentration, Hct, erythrocyte count, serum ferritin concentration, transferrin saturation and serum concentrations of FSH, LH, TE and E2. In patients of the EPO group a marked increase while of the No-EPO group, a slight, but statistically significant increase of the Hct value was found after 9 and 12 months and of E2 concentration after 3, 6, 9 and 12 months of clinical monitoring. In contrast in patients of the EPO group a statistically significant decrease of serum FSH and LH concentrations (during the first 9 months of treatment) and an increase of serum TE and E2 concentrations was observed. From results obtained in this study the following conclusions may be drawn: 1. The degree of anaemia does influence significantly the hormonal profile of the pituitary-gonadal axis in haemodialyzed males with chronic renal failure. 2. rHuEPO therapy for 12 months does exert a significant, although transitory (confined to the first 6-9 months of therapy) suppressive effect on serum follitropin and lutropin levels but increases serum testosterone and estradiol levels in these patients. 3. Alterations of both haematological parameters and of hormone serum levels of the pituitary-gonadal axis observed in EPO treated patients do not seem to be due only to the administration of this hormone.
 ...
PMID:[Influence of long-term erythropoietin (rHuEPO) therapy on the function of the pituitary-gonadal axis in hemodialyzed male patients with end stage renal failure]. 859 49


1 2 3 Next >>